Exciting 30-day trial data has been released by Abeona Therapeutics. Highlights include Gene Therapy has been well-tolerated in low-dose Cohort of first 3 subjects, there has been a significant reduction of Heparan Sulfate in urine and cerebral spinal fluid and subjects have had a reduction in liver and spleen size.